TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
The latest update is out from Cronos Australia Ltd. ( (AU:VIT) ).
Vitura Health Limited has announced an investor webinar to present its FY2025 financial results, highlighting its strategic initiatives and operational advancements. The company’s focus on integrating digital health solutions, such as the Canview platform and telehealth services, positions it as a leader in the Australian healthcare market, with significant opportunities in the distribution of medicinal cannabis and psychedelic products.
The most recent analyst rating on (AU:VIT) stock is a Buy with a A$0.12 price target. To see the full list of analyst forecasts on Cronos Australia Ltd. stock, see the AU:VIT Stock Forecast page.
More about Cronos Australia Ltd.
Vitura Health Limited is a diversified digital health business listed on the ASX, operating through subsidiaries that include Burleigh Heads Cannabis, Canview, Doctors on Demand, Cortexa, Candor Medical, and Flora Holdings. The company focuses on providing a comprehensive healthcare ecosystem, particularly in medicinal cannabis, telehealth services, and psychedelic products for research and therapeutic use in Australia.
Average Trading Volume: 239,854
Technical Sentiment Signal: Sell
Current Market Cap: A$46.69M
For a thorough assessment of VIT stock, go to TipRanks’ Stock Analysis page.